Teva Pharmaceutical Industries (TEVA) Cash from Financing Activities (2016 - 2025)
Historic Cash from Financing Activities for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $40.0 million.
- Teva Pharmaceutical Industries' Cash from Financing Activities rose 10593.47% to $40.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.2 billion, marking a year-over-year decrease of 2010.05%. This contributed to the annual value of -$2.2 billion for FY2025, which is 2010.05% down from last year.
- Teva Pharmaceutical Industries' Cash from Financing Activities amounted to $40.0 million in Q4 2025, which was up 10593.47% from -$453.0 million recorded in Q3 2025.
- In the past 5 years, Teva Pharmaceutical Industries' Cash from Financing Activities registered a high of $40.0 million during Q4 2025, and its lowest value of -$1.7 billion during Q1 2025.
- Moreover, its 5-year median value for Cash from Financing Activities was -$493.0 million (2021), whereas its average is -$500.7 million.
- As far as peak fluctuations go, Teva Pharmaceutical Industries' Cash from Financing Activities plummeted by 3540000.0% in 2023, and later skyrocketed by 10593.47% in 2025.
- Over the past 5 years, Teva Pharmaceutical Industries' Cash from Financing Activities (Quarter) stood at -$501.0 million in 2021, then crashed by 41.92% to -$711.0 million in 2022, then grew by 18.99% to -$576.0 million in 2023, then dropped by 17.01% to -$674.0 million in 2024, then surged by 105.93% to $40.0 million in 2025.
- Its last three reported values are $40.0 million in Q4 2025, -$453.0 million for Q3 2025, and $6.0 million during Q2 2025.